https://www.selleckchem.com/pr....oducts/ly3039478.htm
is infrequent, not associated with mortality, and associated with the use of ipilimumab, ICI combinations and PPIs.Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients' therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using ELISA and their expression on circulating T cells using FACS in pre- and on-treatment blood samples of ICI treated melanoma patients. In addition, pre-treatment melanoma metastas
Like
Comment
Share
